Prevalence and components of metabolic syndrome in HIV-infected patients at the Tiko Central Clinic and Cottage Hospital in Cameroon

Vigny N. Njongang, Assob J. C. Nguedia, Ojong E. Walter


Background: HAART and HIV related metabolic syndrome (MS) is associated with increased cardiovascular risk in aging HIV patients. This study was aimed at comparing the prevalence of MS between HIV-infected patients on HAART and apparently healthy HIV-uninfected individuals and identifying key MS components in these groups of subjects.

Methods: This was a hospital-based case-control study. The cases were HIV sero-positive individuals on HAART for at least 6 months and controls were HIV sero-negative individuals.

Results: 74/135 (54.8%) participants were females amongst which 53/75 (70.7%) and 21/60 (35%) were in the test and control groups respectively. The prevalence of MS was insignificantly higher in HIV-infected patients on HAART than in control subjects according to the IDF (22.7% versus 20%, p=0.834) and NCEP ATP III criteria (18.7% versus 18.3%, p=1.000) respectively. The most prevalent components of MS in HIV-infected patients on HAART were low HDL-c (100%), abdominal obesity (IDF: 68%, ATP III: 32%), and hypertension (28%). Multivariate analysis of MS components in HIV-infected patients on HAART revealed that hypertension (OR: 15.996, 95% CI: 3.385-75.585; p≤0.001) and high blood glucose (OR: 10.760, 95% CI: 1.642-70.505; p=0.013) were associated with MS. Significantly more HIV-infected females were seen with abdominal obesity than HIV-infected males (86.8% versus 4.5%, p≤0.001).

Conclusions: Abdominal obesity is a driving component of MS in HIV-infected patients particularly among females and hypertension is a prevalent and predictor component of MS among HIV patients.


Cardiovascular disease, Components, HAART, HIV, Metabolic syndrome, Prevalence

Full Text:



Sears S, Buendia JR, Odem S, Qobadi M, Wortley P, Mgbere O, et al. Metabolic syndrome among people living with HIV receiving medical care in Southern United States: prevalence and risk factors. AIDS Behav. 2019;23(11):2916-25.

Jules CNA, Vigny N, Vincent SV, John FT, Peter A, Eric AA. Evaluation of cardiovascular risk factors in HIV/AIDS patients attending the Tiko Central Clinic and Cottage hospital, Tiko, Cameroon. Cardiol Cardiovasc Res. 2019;2(3):1-7.

Olamide OT, Solange ZM, Benn S. Prevalence of metabolic syndrome among HIV-positive and HIV-negative populations in sub-Saharan Africa- a systematic review and meta-analysis. BMC Systemat Rev. 2019;8(4):1-17.

Kim AN, Nasheeta P, Edward JM, Andre PK. A meta-analysis of the metabolic syndrome prevalence in the global HIV-infected population. PloS One. 2016;11(3):1-27.

Mariana AR, Geyza NAA, Nathalia SG, Camila AC, Raissa DSS, Unai T. Metabolic disorders and cardiovascular risk in people living with HIV/AIDS without the use of antiretroviral therapy. Rev Soc Bras Med Trop. 2017;50(5):598-606.

Jyothi I, Swaroop N, Suresh S, Nisha G, Rewari BB, Anita S. Metabolic syndrome and cardiovascular disease risk assessment among human immunodeficiency virus-infected individuals on antiretroviral therapy. Indian J Sex Transm Dis. 2018;39(1):28-33.

Alfred O, Tecla MT, Nicholas K, Edmond KN, Jemima HK, Stephanie P, et al. Metabolic syndrome among antiretroviral therapy-naïve versus experienced HIV-infected patients without preexisting cardiometabolic disorders in Western Kenya. AIDS Patient Care STDs. 2018;32(6):215-22.

Agete TH, Demo YT. Influences of gender in metabolic syndrome and its components among people living with HIV virus using antiretroviral treatment in Hawassa, southern Ethiopia. BMC Res Notes. 2016;9(145):1-7.

UNAIDS. HIV/AIDS estimates in Cameroon, 2020. Available at: http://www. countries/countries/Cameroon. Accessed 20 May 2020.

Global AIDS response progress (GARP). National follow-up report on the policy declaration on HIV/AIDS Cameroon, 2014. Available at: Accessed 20 May 2020.

Herbert AM, Henry DM, Anthony TK, Omarine N, Theresia NK. Prevalence of metabolic syndrome in human immunodeficiency virus-infected patients from the South-West region of Cameroon, using the adult treatment panel III criteria. Diabetol Metab Syndr. 2014;6(92):1-7.

Paolo B, Cristina G, Elena R, Rita F, Elena R, Marzia F, et al. HIV and metabolic syndrome: A comparison with the general population. J Acquir Immune Defic Syndr. 2007;45(4):426-31.

Kagaruki GB, Kimaro GD, Mweya CN, Kilale AM, Mrisho RM, Shao AF, et al. Prevalence and risk factors of metabolic syndrome among individuals living with HIV and receiving antiretroviral treatment in Tanzania. J Adv Med Med Res. 2015:1317-27.

Dimodi HT, Etame LS, Nguimkeng BS, Mbappe FE, Ndoe NE, Tchinda JN, et al. Prevalence of metabolic syndrome in HIV-infected Cameroonian patients. World J AIDS. 2014;4:85-92.

Bune GT, Yalew AW, Kumie A. The extents of metabolic syndrome among Antiretroviral Therapy exposed and ART naïve adult HIV patients in the Gedeo-zone, Southern-Ethiopia: a comparative cross-sectional study. Arch Public Health. 2020;78:1-0.

Alvarez C, Salazar R, Galindez J, Rangel F, Castaneda ML, Lopardo G, et al. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Brazilian J Infect Dis. 2010;14(3):256-63.

Lauda LG, Mariath AB, Grillo LP. Metabolic syndrome and its components in HIV-infected individuals. Revista da Associação Médica Brasileira. 2011;57(2):182-6.

Bajaj S, Tyagi SK, Bhargava A. Metabolic syndrome in human immunodeficiency virus positive patients. Indian J Endocr Metab. 2013;17(1):117-20.

International Diabetes Federation. The IDF world consensus definition of the metabolic syndrome. Available at: Accessed 25 May 2020.

American Heart association. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of high blood cholesterol in Adults (adult treatment panel III) Final report. Available at: Accessed 20 May 2020.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52.